Research Topics
| John M LambertSummaryAffiliation: ImmunoGen Inc Country: USA Publications
| Collaborators
|
Detail Information
Publications
Drug-conjugated monoclonal antibodies for the treatment of cancerJohn M Lambert
ImmunoGen Inc, Cambridge, MA 02139, USA
Curr Opin Pharmacol 5:543-9. 2005..Thirty years after the discovery of monoclonal antibodies, this new generation of highly potent compounds could yield targeted cytotoxic agents that are effective treatments for many cancers...
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometryLintao Wang
ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
Protein Sci 14:2436-46. 2005..Using structural models of human IgG1, it was found that modified lysine residues were on the surface in areas of structural flexibility and had large solvent accessibility...- Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometryAlexandru C Lazar
ImmunoGen, Inc, 128 Sidney Street, Cambridge, MA 02139, USA
Rapid Commun Mass Spectrom 19:1806-14. 2005..6 drug molecules per antibody molecule, the experimental conditions needed to be carefully selected to allow acquisition of the whole spectrum containing the charge envelopes of all species... - Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in miceHongsheng Xie
ImmunoGen, Inc, Cambridge, MA 02139, USA
J Pharmacol Exp Ther 308:1073-82. 2004..Tissue distribution studies with (125)I-labeled conjugate and antibody showed antibody-like behavior for the conjugate; the antibody of the conjugate did not distribute or bind significantly to any solid tissue... - A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugatesMichael S Fleming
ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139, USA
Anal Biochem 340:272-8. 2005..The method was also used to estimate drug per MAb ratios, which were consistent with those determined by UV spectroscopy... - Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometryLintao Wang
ImmunoGen, Inc, Cambridge, Maryland 02139, USA
Pharm Res 22:1338-49. 2005..CONCLUSIONS: ESI-TOFMS is a superior tool to characterize MAb and other complex protein pharmaceuticals... - Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
J Clin Oncol 21:211-22. 2003..v.) once every 3 weeks and to seek evidence of antitumor activity... - A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumorsPaul R Helft
University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 10:4363-8. 2004..The evidence of antitumor activity suggests that additional clinical development is warranted, with a focus on tumors that express high levels of CanAg and which are known to be sensitive to antimicrotubule agents... - Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanismJohn M Lambert
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Nat Cell Biol 4:621-5. 2002..Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI(3)K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac... - Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growthAntonio T Baines
Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Methods Enzymol 407:556-74. 2006..Finally, we also compare the use of constitutive and inducible shRNA expression vectors for analyses of mutant Ras function...